NewLimit has secured a fresh $130 million in funding to accelerate its pursuit of therapies that slow cellular aging and extend healthy lifespans. The latest investment round was led by Kleiner Perkins with participation from several new and returning investors, swelling the company’s total raised capital just two years after its last major fundraising effort.
Founded by Brian Armstrong, Blake Byers, and Jacob Kimmel, NewLimit is developing treatments that reprogram aging cells to behave like their younger counterparts. Kimmel highlighted that their lab has produced three experimental drugs capable of reviving aged liver cells, restoring lost abilities like fat and alcohol processing.
Cutting Edge Research Using AI
To gauge breakthroughs, the team compares how reprogrammed old cells perform against naturally young ones, finding that treated cells often regain youthful functions. While these findings are still limited to laboratory settings, human clinical trials are projected to be several years away.
Presently, NewLimit is advancing its anti aging therapies research by leveraging artificial intelligence, using machine generated models to simulate countless experiments before testing the most promising options. Each completed lab experiment yields new data, which gets fed back into the AI system, continually refining future candidates in a cycle Kimmel calls “lab in a loop.”
Other companies are racing toward similar breakthroughs in longevity science. Retro Biosciences, for instance, landed a $180 million investment from Sam Altman, and Altos Labs debuted with $3 billion in funding, attracting backers such as Jeff Bezos.
